WO2004041194A3 - Inhibition of hiv-1 replication - Google Patents

Inhibition of hiv-1 replication Download PDF

Info

Publication number
WO2004041194A3
WO2004041194A3 PCT/US2003/034708 US0334708W WO2004041194A3 WO 2004041194 A3 WO2004041194 A3 WO 2004041194A3 US 0334708 W US0334708 W US 0334708W WO 2004041194 A3 WO2004041194 A3 WO 2004041194A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
inhibition
pnas
taught
compositions
Prior art date
Application number
PCT/US2003/034708
Other languages
French (fr)
Other versions
WO2004041194A2 (en
Inventor
Virendra N Pandey
Neerja Kaushik
Amartya Basu
Paul Palumbo
Rene L Myers
Bechan Sharma
Tanaji T Talele
Ralph A Casale Iii
Original Assignee
Univ New Jersey Med
Applera Corp
Virendra N Pandey
Neerja Kaushik
Amartya Basu
Paul Palumbo
Rene L Myers
Bechan Sharma
Tanaji T Talele
Ralph A Casale Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Jersey Med, Applera Corp, Virendra N Pandey, Neerja Kaushik, Amartya Basu, Paul Palumbo, Rene L Myers, Bechan Sharma, Tanaji T Talele, Ralph A Casale Iii filed Critical Univ New Jersey Med
Priority to AU2003287388A priority Critical patent/AU2003287388A1/en
Publication of WO2004041194A2 publication Critical patent/WO2004041194A2/en
Publication of WO2004041194A3 publication Critical patent/WO2004041194A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions for the inhibition of HIV-1 comprising the use of polyamide nucleic acids (PNAs) that bind to either the transactivation response element or primer binding sequence of the HIV virus are taught. The PNAs may be bound to a membrane transducing peptide, such as transportan. The methods for treating patients infected with HIV or for protecting non-infected patients against HIV infection using the anti-HIV compositions are also taught.
PCT/US2003/034708 2002-11-01 2003-10-31 Inhibition of hiv-1 replication WO2004041194A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003287388A AU2003287388A1 (en) 2002-11-01 2003-10-31 Inhibition of hiv-1 replication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42301502P 2002-11-01 2002-11-01
US60/423,015 2002-11-01

Publications (2)

Publication Number Publication Date
WO2004041194A2 WO2004041194A2 (en) 2004-05-21
WO2004041194A3 true WO2004041194A3 (en) 2005-04-21

Family

ID=32312588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034708 WO2004041194A2 (en) 2002-11-01 2003-10-31 Inhibition of hiv-1 replication

Country Status (2)

Country Link
AU (1) AU2003287388A1 (en)
WO (1) WO2004041194A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1657306B1 (en) * 2004-11-16 2011-04-13 QIAGEN GmbH Gene silencing using sense DNA and antisense RNA hybrid constructs coupled to peptides facilitating the uptake into cells
WO2013111800A1 (en) * 2012-01-25 2013-08-01 独立行政法人科学技術振興機構 Oligonucleotide for hiv detection, hiv detection kit, and hiv detection method
JP2019532027A (en) 2016-08-17 2019-11-07 ソルスティス バイオロジクス，リミティッド Polynucleotide construct
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. Chiral phosphoramidite auxiliaries and methods of their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAUSHIK N. ET AL.: "Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits huamn immunodeficiency virus type 1 production", JOURNAL OF VIROLOGY, vol. 76, no. 8, April 2002 (2002-04-01), pages 3881 - 3891, XP001149279 *

Also Published As

Publication number Publication date
WO2004041194A2 (en) 2004-05-21
AU2003287388A8 (en) 2004-06-07
AU2003287388A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
WO2002096935A3 (en) Long lasting fusion peptide inhibitors for hiv infection
WO2001068116A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections
WO2006013106A3 (en) Vaccine for prevention and treatment of hiv-infection
WO2007081517A8 (en) Anti-viral compounds
GEP20053601B (en) Nucleoside Derivatives as Inhibitors of RNA-Dependent RNA Viral Polymerase
WO2006138259A3 (en) Chemokine receptor binding compounds
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2007084435A8 (en) Methods for treating hepatitis c
WO2005059107A3 (en) Chemokine receptor binding compounds
AU2001232267A1 (en) Remedies for hepatitis c
WO2006138350A3 (en) Chemokine receptor binding compounds
SG178909A1 (en) Generation of a broad t-cell response in humans against hiv
DK1334119T3 (en) Compositions and Methods for Modulating RSV Infection and Immunity
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
WO2004108673A3 (en) Inhibitors of papilloma virus
WO2005076001A3 (en) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
WO2004041194A3 (en) Inhibition of hiv-1 replication
WO2005097179A3 (en) Stabilised tat antigen and the use thereof for anti-hiv vaccination
WO2006109174A3 (en) Hiv vaccine comprising a glycoprotein 120 signal sequence with no more than one positively charged amino acid
WO2007137591A3 (en) Hiv vaccine
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2005027844A3 (en) Dna vaccine compositions and methods of use
WO1999062932A3 (en) INHIBITION OF VIRAL INFECTION AND SPREAD WITH VIRAL AND RhoA-DERIVED PEPTIDES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP